Form 4: Teva Pharmaceutical Executive Eric A. Hughes Reports Share Sales

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, reported the sale of ordinary shares on March 3rd and 4th, 2025, following the vesting of restricted share units.

Summary

• Eric A. Hughes, an Executive Vice President at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Hughes exercised 24,900 restricted share units, converting them into ordinary shares.
• Also on March 3, 2025, Hughes sold 19,726 ordinary shares at an average price of $16.1855.
• On March 4, 2025, Hughes sold an additional 5,174 ordinary shares at an average price of $15.5576.
• Following these transactions, Hughes directly owns 5,174 ordinary shares and 49,801 restricted share units.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing share transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted share units.

Industry Context

Executive share sales are a common occurrence in publicly traded companies and are often related to compensation and personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive compensation packages often include restricted share units that vest over time, aligning executive interests with long-term shareholder value.
• Rule 10b5-1 trading plans are a standard practice for executives to sell shares while avoiding accusations of insider trading; many companies such as Pfizer, Johnson & Johnson, and Merck have executives who utilize these plans.
• The volume of shares sold is relatively small compared to the overall market capitalization of Teva, suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The share sales by an executive could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the executive's motivations.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates